CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
LY3039478 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02906618
NCT02906618Phase 1Completed
CompareCT.gov

An Absolute Bioavailability Study of LY3039478 in Healthy Subjects Using the Intravenous Tracer Method

Eli Lilly and Company·interventional·Posted Sep 20, 2016·Updated Jul 9, 2025

In Brief

A Phase 1 clinical trial evaluating LY3039478 and 13C 15N 2H-LY3039478 IV for Healthy. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The study involves one dose of LY3039478 given by mouth followed by an intravenous infusion (IV) (via a tube linked to a small needle in the vein) of LY3039478. The results of this study will help to answer the following research questions: * How much LY3039478 gets into the blood stream when given by mouth as a capsule compared to when given by an IV * How long it takes the body to remove the study drug * The safety of LY3039478 and any side effects that might be associated with it Participation in the study is expected to last up to 7 weeks. There will be screening, a single study period, and a follow-up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 20, 2016
Enrollment StartOct 4, 2016
Primary CompletionNov 11, 2016
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 9.8 years ago

Interventions

LY3039478drug

Administered orally

13C 15N 2H-LY3039478 IVdrug

Administered IV